Effect of Diabetes Mellitus on short-term prognosis of 227 pyogenic liver abscess patients after hospitalization

CURRENT STATUS: ACCEPTED

BMC Infectious Diseases ▪ BMC Series

Zhaoqing Du
Xi'an Jiaotong University

Xinchen Zhou
Xi'an Jiaotong University

Junzhou Zhao
Xi'an Jiaotong University

Jianbin Bi
Xi'an Jiaotong University

Yifan Ren
Xi'an Jiaotong University

Jia Zhang
Xi'an Jiaotong University

Yuxin Lin
Xi'an Jiaotong University

Zheng Wu
Xi'an Jiaotong University

Yi IV
Xi'an Jiaotong University

XuFeng Zhang
Xi'an Jiaotong University

Rongqian Wu
National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine
rwu001@mail.xjtu.edu.cn

Corresponding Author

ORCID: https://orcid.org/0000-0003-0993-4531
Abstract

Background: Pyogenic liver abscess (PLA) is an inflammatory disease with increasing incidence. When it occurs with diabetes mellitus (DM), risk of recurrence and the mortality may increase. However, the effect of DM on short-term prognosis of PLA patients after hospitalization remained unknown.

Methods: 227 PLA patients who received treatment at the First Affiliated Hospital of Xi’an Jiaotong University from January 2011 to January 2018 were retrospectively enrolled. They were divided into two groups as DM group (n=61) and Non-DM group (n=166). In the DM group, HbA1C level <7% was considered to be good-control of glycaemia (n=23). The clinical characteristics and overall short-term survivals were analyzed.

Results: The proportion of PLA patients with DM was 26.87%. In the DM group, there was a higher incidence of hypertension and Candida spp. infection. Conservative administration and percutaneous drainage were mainly used in patients with good- (60.87%) and poor-control (60.53%) of glycaemia, respectively. During follow-up, 24 (10.57%) died due to uncontrolled systemic infections and other serious complications. Compared with PLA patients without DM, patients in the DM group had significantly increased 6-month mortality rate after discharge (Log-Rank test, P =0.021). Poor-control of glycaemia did not reduce the six-month survival, while the recurrence rate of PLA within three months showed an almost 3-fold increase (13.16% vs. 4.35%). Further multivariate analyses found that DM was the only independent risk factor for the PLA six-month survival (odd ratio [OR]: 0.097, 95% confidence interval [CI]: 0.018-0.526, P =0.007). However, the blood glucose level had no significant effect on the short-term survival of PLA patients with DM (Log-Rank test, P =0.218).

Conclusions: In PLA patients, DM aggravated short-term mortality and blood glucose levels should be well controlled.

Background

Pyogenic liver abscess (PLA), as a serious infectious disease occurs in liver parenchyma, has shown a trend of increasing incidence and high mortality recently [1]. Researchers found that PLA had different prevalence in general population over the world, with a ranging from 3.6 per 10,000 population [2] in Europe and Americas to 17.6–86 per 10,000 population [1, 3] in Asia. Because it can
cause fatal systemic infections, mortality rate of PLA within 30 days of hospitalization can be as high as 10% [4]. Especially in the case of combining high risk factors or underlying conditions, it may be easier to induce serious complications and worsen prognosis [5].

PLA patients with DM is a relatively popular situation, the rate can be up to 35.3% [4]. Meanwhile, DM status may easier result in severe complications and recurrent [6]. In addition, poor-control of blood glucose may aggravate the situation and prognosis [7]. However, the clinical characteristics and short-term survival between PLA patients with and without DM have not been fully discussed before, especially in northwest China. Moreover, rare research has been published about the effect of blood glycaemic control on these aspects of PLA patients with DM. In this study, we conducted a retrospective study on PLA patients with or without DM, and with good or poor control of blood glucose level, comparing their clinical characteristics and short-term survivals, which might help improving the diagnosis and prognosis of PLA patients with DM and provide clues of the effect of glycaemic control.

Patients And Methods

Patients

In this retrospective study, we examined the patients who were diagnosed primarily as PLA in the First Affiliated Hospital of Xi’an Jiaotong University between January 2011 to January 2018. All diagnoses of PLA were based on the clinical features, imaging and laboratory results, blood and pus cultures. Details of 422 patients were retrieved through the hospital’s electronic medical record system. Patients with the following conditions were excluded: those who were diagnosed malignant tumors or other serious cardiovascular diseases, those who were not the first time suffering from liver abscess, those who had not finished the hospitalization in our center and those who had incomplete medical records or a 180 days follow-up. Finally, 227 patients entered this study. Patients were firstly divided into two groups based on the diagnoses with or without diabetes, and then the patients with diabetes were further divided into two subgroups, good- and poor-control groups of glycaemia. Patients of type II diabetes mellitus all had a clear history of diabetes at admission, and none of them were diagnosed after admission. We defined DM patients with HbA1C level <7% included in the good-
control group and ≥7% in the poor-control group. This study was strictly complied with the Treaty of Helsinki and approved by the ethics committee of the First Affiliated Hospital of Xi’an Jiaotong University. Written informed consent were waived as a retrospective research.

Data collection

All data were collected from the electronic medical records system. The general data we extracted included age, sex, symptoms and signs, underlying conditions, hepatitis status, cost and length of hospital stay. Laboratory results at admission were obtained, containing blood routine, liver function, renal function, coagulation, blood and pus culture data, plasma glucose and HbA1C level. Complications, treatments and outcomes were also gained. Abscess number, diameter, site and gas forming were measured by ultrasonography and computerized tomography (CT).

Follow-up

Follow-up for all patients was until June 2018 and lasted for at least 6 months after discharge. The average follow-up time was 820 (IQR: 308, 1261) days. The main contents of the follow-up included the disease status, recurrence, and mortality of the patients. To minimize the bias, the follow-up was completed by two clinical researchers independently.

Statistical Analysis

For continuous variables, the study was expressed as mean ± standard deviation or median (min-max) whereas categorical variables used frequency and percentage. To calculate the difference between the two groups, we applied the Student’s t-test or Wilcoxon test for continuous variables and the chi-squared test or Fisher’s exact test for categorical data. For three or more groups, we applied the analysis of variance. The factors that found \( P<0.10 \) in the univariate analysis were further estimated through the multivariate analysis. Survival curves were calculated by the Kaplan–Meier curve method, and statistical differences was calculated through Log-Rank test. All statistical analyzes were finished by SPSS 23.0 software (IBM Corporation, Armonk, NY, USA). Graphpad prism 8.0 software was used to beautified the survival curves (GraphPad Software, Inc. La Jolla, USA). \( P<0.05 \) was considered as statistically significant.

Results
Demographic and clinical characteristics

A total of 227 patients with PLA were enrolled in this retrospective study. As shown in Table 1, the average age of total patients was 56 years (range: 11–84 years), and 135 (59.47%) of them were male. Among them, 66 (29.07%) patients had a history of smoking, 43 (18.94%) patients had alcohol drinking history. 43 (18.94%) and 8 (3.52%) patients had hypertension and cirrhosis, respectively. Most patients had a normal (60.79%) or low-grade fever temperature (34.80%) at admission, and the medium time for temperature normalization was 6.39 (range: 0–40). Leucocytes abnormally increased in 119 patients (52.42%) on the first day of admission. In this cohort, the number of abscess was mainly single (75.77%). The maximum diameter of the abscess in 132 patients (58.15%) was between 5 and 10 cm, and followed by small abscess in 75 cases (33.04%). In 137 (60.35%) patients, the abscess was located in the right liver lobe, 34 (14.98%) in the left, and 41 (18.06%) in the both. Gas formation were observed in 45 patients (19.82%). In Table 2, 114 patients (85.07%) were Gram-negative bacteria, 18 (13.43%) were Gram-positive bacteria, and 2 (1.49%) were Candida spp. infections. Klebsiella pneumonia and Escherichia coli in the Gram-negative organisms were the two most common bacteria in this study, accounting for 57.44% and 17.91%, respectively. In the Gram-positive organisms, Streptococcus spp. (6.72%) was the most pathogens cultured. It was documented that pleural and celiac effusion were the most common complications (18.41%, and 7.58%, respectively, Table 3). 136 (59.91%) patients received percutaneous drainage, 28 (12.33%) underwent surgical drainage, and the rest 63 (27.75%) were administrated conservative treatment. 125 (55.07%) patients presented combined antibiotic use. All patients showed outcomes with cured or improved and no patient died during hospital stay. The average costs of total patients was 28,700 yuan.

Associations between Diabetes Mellitus and patients characteristics

In this study, 227 patients were divided into two groups based on DM. The Non-DM group included 166 (73.13%) patients and the DM group included 61 (26.87%) patients, with an average diabetes
duration time of 5.5 years (range: 0.2–30 years). There was no significant difference in gender, age, the body temperature at admission, abscess number, size, site, and gas forming between the two groups (Table 1). However, patients in DM group exhibited more hypertension but lower leucocytes counts ($P<0.001$, and $P = 0.007$, respectively). Although the infection of Gram-negative and –positive in this study were similar between the two groups, patients in DM group had higher *Candida* spp.

infection than that of in Non-DM group ($P = 0.049$, Table 2). In Table 3, no significant difference had been found in complications, intravenous antibiotics use, outcomes, hospital stay, total costs and reoccurrence in three months between the two groups. While the choice of treatments were different between the two groups ($P = 0.024$). Percutaneous drainage was mainly adopted in patients without DM (64.46%), while percutaneous drainage and conservative treatment were mainly performed in patients with DM (47.54% and 40.98%).

**Effect of Diabetes Mellitus on short-term survival in liver abscess patients**

During the follow-up period, 24 (10.57%) died within six months and 14 (6.17%) were diagnosed with PLA recurrence within three months after discharge. The PLA patients with DM had a lower six-month survival than that of in Non-DM group (81.97% vs. 92.17%, $P = 0.027$) and no significant difference had been found with reoccurrence rate between the two groups ($P = 0.164$, Table 3). To explore risk factors independently associated with short-term survival after hospitalization in PLA patients, univariable and multivariable analysis were made. Univariate variables with $P<0.10$ were further analyzed with multivariate model. As shown in Table 4, diabetes mellitus (OR: 0.097, 95% CI: 0.018–0.526, $P = 0.007$) was the only independent risk factor for six-month survival after discharge. Other factors including age >60 years, gender, cirrhosis, biliary tract infection, abscess number and size, gas forming, *Escherichia coli* infection, and treatments methods were not found to be independent risk factors. The Kaplan-Meier curve of six-month survival after discharge was further estimated with regard to DM in Figure 1. It was found that PLA patients with DM had worse short-term survival than those in Non-DM group (Log-Rank test, $P = 0.021$).
Subgroups analysis in PLA patients with DM

Abnormal glycaemia level in the DM group was considered to be a potent risk factor of short-term survival in PLA patients, which was further investigated in subgroups. All the patients were classified into two subgroups according to the HbA1C level. The clinical characteristics, laboratory results, abscess information, treatments and outcomes were compared between the two subgroups in Table 5. No difference was presented between the two subgroups in age, gender, diabetes duration time, underlying conditions, laboratory tests, abscess characteristics, outcomes, and hospital stay, etc. However, there was an obvious difference in the selection of treatments between the two subgroups ($P = 0.027$). Percutaneous drainage was mainly performed in patients with poor-control of glycaemia (60.53%) and conservative treatment was mainly adopted in patients with good-control of glycaemia (60.87%). Besides, combined intravenous antibiotic showed a higher proportion in poor-control group (71.05%, $P = 0.033$). Although there was no significant difference, total hospitalization costs and relapsed PLA within three months after discharge showed an obvious increase in the poor-control group compared to good-control group (42,300 vs. 22,100 yuan, 13.16% vs. 4.35%, respectively). Kaplan-Meier curve with different glycaemia levels in terms of six-month survival was shown in Figure 2. No difference was unfolded between the two groups in Kaplan-Meier plots (Log-Rank test, $P = 0.218$).

Discussion

The increasing incidence and high mortality of PLA patients with diabetes mellitus has become an important health problem in hepatobiliary system that plagues humans [6]. As a risk factor for PLA, DM can directly lead to liver damage, abnormal bile secretion, and increasing portal vein infection [8-10]. DM can also cause systemic metabolic disorders and impaired immunity, which weakens the ability of the liver to clear bacteria, making the bacteria easy to colonize and multiply to form abscesses [11]. Studies have confirmed that although the incidence of DM in PLA patients is regionally different in Asia, Europe, and America, it still can be as high as 23% to 44.9% [7, 12-14]. Even in PLA patients caused by *Klebsiella pneumonia*, the incidence of DM is higher as 49.7%. 
Unexpectedly, this number is likely to grow in recent years with the increasing PLA [14]. In this study, the ratio reached 26.87%.

PLA and DM are high consumption diseases and often progress rapidly when both occur. Meanwhile, the development of PLA has obvious periodicity, and the mortality rate is high during the onset period [15]. Combined with DM in PLA patients should have significant impact on overall survival, especially in the short onset period. Researchers believe that the physique of DM patients tends to be fragile, when suffered with PLA, the condition will be complicated and the mortality will be higher [16]. They discovered that PLA patients with and without DM had a mortality rate of 24.8% and 18.0% within 30 days after discharge, respectively [16]. However, other studies agreed that DM was not an independent risk factor for prognosis in PLA patients [3, 6]. In this study, six-month follow-up was performed on 227 PLA patients who were retrospectively enrolled. We found that the overall mortality rate was 10.57% within six-months after discharge, which was slightly lower than similar studies [15]. Moreover, DM existed as the only independent risk factor for six-month survival in PLA patients after hospitalization in this cohort and other high risk factors, such as age > 60 years, cirrhosis, diameter of abscess, and gas forming were not statistically significant in the multivariate model [15, 17].

Compared with 7.83% in PLA patients without DM, the mortality dramatically increased to 18.03% in patients with DM. In the further subgroups, poor-control of glycaemia didn’t reduce the short-term survival, but the recurrence rate of PLA within 3 months after discharge showed a 3-fold increase (13.16% vs. 4.35%). It can be interpreted as poor-control of glycaemia inducing a higher infection and more abscess numbers by a recent similar study [7].

In PLA patients with DM, blood pressure was significant high, which suggested that these cases had vascular diseases [18]. Unexpectedly, leukocytes counts showed a higher abnormal at admission in the Non-DM group, which might be related to the heavier inflammatory status in this group. Bacterial culture revealed that Klebsiella pneumonia and Escherichia coli were still the two most common infectious pathogens, whether or not combined with DM [6, 12, 19]. Interestingly, pus culture results illustrated 2 cases of Candida spp. infection in the DM group. Candida spp. is rare in PLA, but it is highly related to mortality [20]. The infection rate of candida spp. in this study was only 0.88%
(2/227), but all occurred in DM group, probably due to the vulnerable immune system in these cases. Besides, DM patients maybe more common in gas forming [21], but slightly higher rate has been found in this study (24.59% vs. 18.07%). The administration of PLA with DM is commonly more complex than simple PLA. Hyperglycemia in tissue easily causes cell hyperosmosis, regeneration and repair function weakening, which then may delay puncture heling [22]. In our study, PLA patients without DM were mainly operated with percutaneous drainage, while in DM group, percutaneous drainage and simple conservative management were mainly used. Interestingly, in the further subgroups, patients with poor blood glycemic control were mainly performed with percutaneous drainage, while patients with good control were mostly treated with conservative method. It seems that the diameter of abscesses in poor-controlled group is generally larger in this study [23]. In the poor-control of glycaemia group, PLA patients with maximum diameter of abscess $\geq$5 cm accounted for 65.79%, while those in good-control group were only 52.17% [24]. It was notable that the poor-controlled group had a higher proportion of combined antibiotic administration and the good-controlled group presented with single antibiotic [7]. In addition, the hospitalization cost in poor-controlled group was twice that of the good-controlled group, although there was no significant difference in hospital stay between the two groups [25].

Previous studies have shown that gas forming nature and higher creatinine are risk predictors of fatality for PLA patients [6]. However, in our multivariate model, they were not illustrated to be independent risk factors affecting six-month survival after hospitalization. The limitations of this study are mainly focused on its retrospective and single-centered traits, while because of its large sample size, the conclusions we have gained can still be used as helpful reference for other researchers and clinicians, especially further enriching the experience of diagnosis and treatment of PLA patients with DM in northwestern China. Moreover, as the follow-up time in the present study was only six months, further longer follow-up and expanded sample size will be needed to comment on the long-term administrations and outcomes of PLA patients with DM.

Conclusion
Underlying with DM is common in PLA patients, whose epidemiology and administrations shows
unique specificities. PLA patients with DM have higher incidence of hypertension and Candida spp. infection. In the DM group, patients were mainly treated with conservative method and more combined antibiotics use. During the follow-up period, DM group showed a higher mortality rate than that in the Non-DM group. It was found that DM aggravated six-month mortality after hospitalization and presented to be the only independent risk factor for the short-term survival in PLA patients. Moreover, poor-control of glycaemia level might cause different treatments and relapse PLA more frequently. Hence, DM is an important risk factor for PLA patients and effective management of blood glucose levels should be recommended.

Declarations

List of abbreviations: PLA: Pyogenic liver abscess; WBC: white blood cell; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: Albumin; PT: prothrombin time; APTT: activated partial thromboplastin time; BUN: blood urea nitrogen; Cr: creatinine; DM: diabetes mellitus; Non-DM: non-diabetes mellitus.

Acknowledgements: We thank supports from the department of Hepatobiliary Surgery of the First Affiliated Hospital of Xi’an Jiaotong University and China Scholarship Council.

Funding: This work was supported by a grant from the Ministry of Education Innovation Team Development Program of China (No. IRT16R57, YL).

Availability of data and materials: All data used or analyzed in this study are included in this published article.

Authors’ contributions: Conceptualization: RW, XZ; Data curation: ZD, XC, JZ, JB, YL. Formal analysis: ZD, JZ, XC; Validation: XC; Funding acquisition: RW; Investigation: ZD, XC, JZ, JB, JZ, RY; Methodology: ZD, XC, JZ, JB, JZ, RY; Project administration: XZ, RW; Resources: ZW, YL; Supervision: RW, XZ; Visualization: ZD, RW; Writing—original draft: ZD; Writing—review & editing: RW.

Ethics approval and consent to participate: This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (XJTU1AF2015LSL-057). Written informed consent were waived as a retrospective research. There was not further permission from the hospital.

Consent for publication: Not applicable.
Competing interests: The authors declare no competing financial interests.

References

1. Lo JZ, Leow JJ, Ng PL, Lee HQ, Mohd Noor NA, Low JK, Junnarkar SP, Woon WW: Predictors of therapy failure in a series of 741 adult pyogenic liver abscesses. *Journal of hepato-biliary-pancreatic sciences* 2015, 22(2):156–165.

2. Meddings L, Myers RP, Hubbard J, Shaheen AA, Laupland KB, Dixon E, Coffin C, Kaplan GG: A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. *The American journal of gastroenterology* 2010, 105(1):117–124.

3. Tsai FC, Huang YT, Chang LY, Wang JT: Pyogenic liver abscess as endemic disease, Taiwan. *Emerging infectious diseases* 2008, 14(10):1592–1600.

4. Chen YC, Lin CH, Chang SN, Shi ZY: Epidemiology and clinical outcome of pyogenic liver abscess: an analysis from the National Health Insurance Research Database of Taiwan, 2000–2011. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi* 2016, 49(5):646–653.

5. Gallagher MC, Andrews MM: Postdischarge Outcomes of Pyogenic Liver Abscesses: Single-Center Experience 2007–2012. *Open forum infectious diseases* 2017, 4(3):ofx159.

6. Foo NP, Chen KT, Lin HJ, Guo HR: Characteristics of pyogenic liver abscess patients with and without diabetes mellitus. *The American journal of gastroenterology* 2010, 105(2):328–335.

7. Li W, Chen H, Wu S, Peng J: A comparison of pyogenic liver abscess in patients with or without diabetes: a retrospective study of 246 cases. *BMC gastroenterology* 2018, 18(1):144.

8. Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, Salvatore T, Sasso FC, Tripodi MF, Persico M: Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. *PLoS One* 2017, 12(6):e0178473.

9. Gonzalez-Regueiro JA, Moreno-Castaneda L, Uribe M, Chavez-Tapia NC: The Role of Bile Acids in Glucose Metabolism and Their Relation with Diabetes. *Ann Hepatol* 2017, 16(Suppl. 1: s3-105.):16–21.

10. Mithieux G: Metabolic effects of portal vein sensing. *Diabetes Obes Metab* 2014, 16 Suppl 1:56–60.

11. Tian LT, Yao K, Zhang XY, Zhang ZD, Liang YJ, Yin DL, Lee L, Jiang HC, Liu LX: Liver abscesses in adult patients with and without diabetes mellitus: an analysis of the clinical characteristics, features
of the causative pathogens, outcomes and predictors of fatality: a report based on a large population, retrospective study in China. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2012, 18(9):E314–330.

12. Serraino C, Elia C, Bracco C, Rinaldi G, Pomero F, Silvestri A, Melchio R, Fenoglio LM: Characteristics and management of pyogenic liver abscess: A European experience. Medicine 2018, 97(19):e0628.

13. Mukthinuthalapati V, Attar BM, Parra-Rodriguez L, Cabrera NL, Araujo T, Gandhi S: Risk Factors, Management, and Outcomes of Pyogenic Liver Abscess in a US Safety Net Hospital. Dig Dis Sci 2019.

14. Qian Y, Wong CC, Lai S, Chen H, He X, Sun L, Wu J, Zhou J, Yu J, Liu W et al: A retrospective study of pyogenic liver abscess focusing on Klebsiella pneumoniae as a primary pathogen in China from 1994 to 2015. Sci Rep 2016, 6:38587.

15. Poovorawan K, Pan-Ngum W, Sonthornworasiri N, Kulrat C, Kittitrakul C, Wilairatana P, Treeprasertsuk S, Kitsahawong B, Phaosawasdi K: Burden of Liver Abscess and Survival Risk Score in Thailand: A Population-Based Study. The American journal of tropical medicine and hygiene 2016, 95(3):683–688.

16. Thomsen RW, Jepsen P, Sorensen HT: Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2007, 44(9):1194–1201.

17. Jun CH, Yoon JH, Wi JW, Park SY, Lee WS, Jung SI, Park CH, Joo YE, Kim HS, Choi SK et al: Risk factors and clinical outcomes for spontaneous rupture of pyogenic liver abscess. Journal of digestive diseases 2015, 16(1):31–36.

18. Ohishi M: Hypertension with diabetes mellitus: physiology and pathology. Hypertension research: official journal of the Japanese Society of Hypertension 2018, 41(6):389–393.

19. Xu J, Zhou X, Zheng C: The geriatric nutritional risk index independently predicts adverse outcomes in patients with pyogenic liver abscess. BMC geriatrics 2019, 19(1):14.

20. Ruiz-Hernandez JJ, Leon-Mazorra M, Conde-Martel A, Marchena-Gomez J, Hemmersbach-Miller M, Betancor-Leon P: Pyogenic liver abscesses: mortality-related factors. European journal of
gastroenterology & hepatology 2007, 19(10):853–858.

21. Thng CB, Tan YP, Shelat VG: Gas-forming pyogenic liver abscess: A world review. Annals of hepatobiliary-pancreatic surgery 2018, 22(1):11–18.

22. Baltzis D, Eleftheriadou I, Veves A: Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Advances in therapy 2014, 31(8):817–836.

23. Mobasher-Jannat A, Akhavan-Moghadam J: Percutaneous drainage for giant pyogenic liver abscess—does size matter? American journal of surgery 2017, 214(4):770.

24. Ko MC, Lin WH, Martini S, Chang YH, Chiu CT, Li CY: A cohort study of age and sex specific risk of pyogenic liver abscess incidence in patients with type 2 diabetes mellitus. Medicine 2019, 98(17):e15366.

25. Kang SC, Hwang SJ: Impact of advanced age on inpatients with pyogenic liver abscess in Taiwan: a Nationwide claim-based analysis. Journal of the Chinese Medical Association: JCMA 2011, 74(12):539–543.

Tables

**Table 1.** Clinical characteristics of the 227 patients with pyogenic liver abscess patients with diabetes or without diabetes presented at admission.
| Values                          | Median (range)/n (percentage) | Diabetes Mellitus | Non-Diabetes Mellitus | p value |
|--------------------------------|-------------------------------|-------------------|-----------------------|---------|
| n                              | 227                           | 61 (26.87%)       | 166 (73.13%)          | 0.837   |
| Age (years)                    | 56 (11-84)                    | 57 (22-84)        | 56 (11-84)            |         |
| Gender (male)                  | 135 (59.47%)                  | 39 (63.93%)       | 96 (57.83%)           | 0.406   |
| Underlying conditions          |                               |                   |                       |         |
| Smoking                        | 66 (29.07%)                   | 16 (26.23%)       | 50 (30.12%)           | 0.567   |
| Drinking                       | 43 (18.94%)                   | 33 (19.88%)       | 10 (16.39%)           | 0.552   |
| Hypertension                   | 43 (18.94%)                   | 31 (50.82%)       | 12 (7.23%)            | <0.001  |
| Cirrhosis                      | 8 (3.52%)                     | 2 (3.28%)         | 6 (3.61%)             | 0.902   |
| Body temperature at admission (°C) |                             |                   |                       |         |
| 35.5°C~37.3 °C                 | 138 (60.79%)                  | 42 (68.85%)       | 96 (57.83%)           | 0.319   |
| 37.4 °C~39 °C                  | 79 (34.80%)                   | 17 (27.87%)       | 62 (37.35%)           |         |
| >39.1 °C                       | 10 (4.41%)                    | 2 (3.28%)         | 8 (4.82%)             |         |
| Time for temperature normalization (days) |                     |                   |                       |         |
| WBC > 10 x 10^9/L              | 119 (52.42%)                  | 23 (37.70%)       | 96 (57.83%)           | 0.007   |
| WBC < 3.5 x                   | 4 (1.76%)                     | 3 (4.92%)         | 1 (0.60%)             | 0.105   |
| ALT > 40 U/L                   | 108 (47.58%)                  | 25 (40.98%)       | 83 (50.00%)           | 0.228   |
| AST > 40 U/L                   | 67 (29.52%)                   | 15 (24.59%)       | 52 (31.33%)           | 0.324   |
| ALB < 35 g/L                   | 169 (74.45%)                  | 45 (73.77%)       | 124 (74.70%)          | 0.887   |
| TBIL > 17 μmol/L               | 96 (42.29%)                   | 31 (50.82%)       | 65 (39.16%)           | 0.115   |
| PT > 17 s                      | 20 (8.81%)                    | 6 (9.84%)         | 14 (8.43%)            | 0.741   |
| APTT > 45 s                    | 26 (11.45%)                   | 7 (11.48%)        | 19 (11.45%)           | 0.995   |
| BUN > 7.2                      | 16 (7.27%)                    | 7 (11.67%)        | 9 (5.63%)             | 0.213   |
| Cr > 97 μmol/L                 | 30 (13.64%)                   | 7 (11.67%)        | 23 (14.37%)           | 0.602   |
| Abscess number                 |                               |                   |                       |         |
| Solitary abscess               | 172 (75.77%)                  | 47 (77.05%)       | 125 (75.30%)          | 0.785   |
| Multiple abscess               | 55 (24.23%)                   | 14 (22.95%)       | 41 (24.70%)           |         |
| Maximal diameter of abscess    |                               |                   |                       |         |
| ≤ 5 cm                         | 75 (33.04%)                   | 24 (39.34%)       | 51 (30.72%)           | 0.116   |
| 5~10 cm                        | 132 (58.15%)                  | 34 (55.74%)       | 98 (59.04%)           |         |
| > 10 cm                        | 20 (8.81%)                    | 3 (4.92%)         | 17 (10.24%)           |         |
| Abscess site                   |                               |                   |                       |         |
| Left lobe                      | 34 (14.98%)                   | 6 (9.84%)         | 28 (16.87%)           | 0.289   |
| Right lobe                     | 137 (60.35%)                  | 43 (70.49%)       | 94 (56.63%)           |         |
| Both left and right            | 41 (18.06%)                   | 9 (14.75%)        | 32 (19.28%)           |         |
| Other sites                    | 15 (6.61%)                    | 3 (4.92%)         | 12 (7.23%)            |         |
| Gas forming                    | 45 (19.82%)                   | 15 (24.59%)       | 30 (18.07%)           | 0.275   |

**WBC**: white blood cell; **ALT**: alanine transaminase; **AST**: aspartate transaminase; **ALB**: albumin; **TBIL**: total bilirubin; **PT**: prothrombin time; **APTT**: activated partial thromboplastin time; **BUN**: blood urea nitrogen; **Cr**: creatinine.

**Table 2.** Blood and pus cultures in pyogenic liver abscess patients with diabetes mellitus (DM) and non-diabetes mellitus (Non-DM).
| Values                  | Blood culture | Pus culture | P value | Blood culture | Pus culture | P value |
|------------------------|---------------|-------------|---------|---------------|-------------|---------|
|                        | DM (n = 43)   | Non-DM (n = 136) | P value | DM (n = 42)   | Non-DM (n = 145) | P value |
| Positive results       | 35            | 118         | 0.384   | 19            | 71          | 0.670   |
| Polymicrobial results  | 2             | 5           | 1.000   | 3             | 2           | 0.135   |
| Gram-negative organisms|               |             |         |               |             |         |
| Klebsiella pneumonia   | 3             | 12          | 0.948   | 15            | 47          | 0.689   |
| Escherichia coli       | 4             | 3           | 0.101   | 5             | 12          | 0.678   |
| Pseudomonas aeruginosa | 1             | 0           | 0.240   | 2             | 1           | 0.127   |
| Enterobacter cloacae   | 0             | 0           | –       | 0             | 2           | 1.000   |
| Proteus spp.           | 0             | 0           | –       | 0             | 2           | 1.000   |
| Serratia fonticola     | 0             | 1           | 1.000   | 0             | 0           | –       |
| Salmonella enteritidis | 0             | 0           | –       | 1             | 0           | 0.223   |
| Klebsiella oxytoxa     | 0             | 0           | –       | 0             | 1           | 1.000   |
| Bacillus citrate       | 0             | 0           | –       | 0             | 1           | 1.000   |
| Stenotrophomonas maltophilia | 0   | 0           | –       | 1             | 0           | 0.225   |
| Gram-positive organisms|               |             |         |               |             |         |
| Streptococcus spp.     | 1             | 1           | 0.424   | 0             | 7           | 0.322   |
| Enterococcus spp.      | 2             | 0           | 0.057   | 0             | 3           | 1.000   |
| Clostridium spp.       | 0             | 2           | 1.000   | 0             | 0           | –       |
| Staphylococcus spp.    | 0             | 1           | 1.000   | 0             | 1           | 1.000   |
| Candida spp.           | 0             | 0           | –       | 2             | 0           | **0.049** |

**Table 3.** Complications, treatments, outcomes and survival of the pyogenic liver abscess patients with diabetes mellitus and non-diabetes mellitus.
| Variables                        | Median (range)/n (percentage) | Diabetes Mellitus | Non-Diabetes Mellitus | p value |
|---------------------------------|------------------------------|------------------|-----------------------|---------|
| **Complications**               |                              |                  |                       |         |
| Bile leakage                    | 9 (3.96%)                    | 2 (3.28%)        | 7 (4.22%)             | 1.000   |
| Intrapertitoneal bleeding       | 10 (4.41%)                   | 3 (4.92%)        | 7 (4.22%)             | 0.731   |
| Plumonary infection             | 5 (2.20%)                    | 2 (3.28%)        | 3 (1.81%)             | 0.613   |
| Pleural effusion                | 51 (18.41)                   | 17 (27.87%)      | 34 (20.48%)           | 0.237   |
| Celiac effusion                 | 21 (7.58)                    | 8 (13.11%)       | 13 (7.83%)            | 0.208   |
| **Treatments**                  |                              |                  |                       |         |
| Percutaneous drainage           | 136 (59.91%)                 | 29 (47.54%)      | 107 (64.46%)          | 0.024   |
| Surgical drainage               | 28 (12.33%)                  | 7 (11.48%)       | 21 (12.65%)           |         |
| Conservative treatment          | 63 (27.75%)                  | 25 (40.98%)      | 38 (22.89%)           |         |
| Antibiotic use                  |                              |                  |                       |         |
| Combined                         | 125 (55.07%)                 | 37 (60.66%)      | 88 (53.01%)           | 0.305   |
| Single                           | 102 (44.93%)                 | 24 (39.34%)      | 78 (46.99%)           |         |
| **Outcomes**                    |                              |                  |                       |         |
| Cured                            | 155 (68.28%)                 | 45 (73.77%)      | 110 (66.27%)          | 0.282   |
| Improved                         | 72 (31.72%)                  | 16 (26.23%)      | 56 (33.73%)           |         |
| Death                            | 0 (0%)                       | 0 (0%)           | 0 (0%)                |         |
| Hospital stay (days)            | 14 (2-52)                    | 15 (3-40)        | 14 (2-52)             | 0.444   |
| Total                            | 2.87 (0.27-19.03)            | 2.97 (0.27-19.03)| 2.84 (0.33-12.65)    | 0.748   |
| Hospitalization expenses (× 10000 yuan) |                     |                  |                       |         |
| Reoccurrence in three months    | 14 (6.17%)                   | 6 (9.84%)        | 8 (21.05%)            | 0.164   |
| Survival (yes/no) in six months | 203 (89.43%)                 | 50 (81.97%)      | 153 (92.17%)          | 0.027   |

*Table 4.* Univariate and multivariate analysis of factors associated with PLA six-month survival.
| Variables                     | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
|                               | P       | OR (95%CI)           | P       | OR (95%CI) |
| Age > 60 years                | 0.284  | 2.261 (0.517-9.507)  |         |            |
| Gender (male)                 | 0.212  | 0.395 (0.092-1.627)  |         |            |
| Smoking (yes/no)              | 0.595  | 1.486 (0.345-6.404)  |         |            |
| Drinking (yes/no)             | 0.658  | 1.447 (0.282-7.430)  |         |            |
| Hypertension (yes/no)         | 0.658  | 1.447 (0.282-7.430)  |         |            |
| Cirrhosis (yes/no)            | 0.197  | 4.327 (0.467-40.094) |         |            |
| Diabetes (yes/no)             | 0.008  | 8.945 (1.754-45.619) | 0.007  | 0.097 (0.018-0.526) |
| Biliary tract infection (yes/no) | 0.868 | 0.835 (0.099-7.015)  |         |            |
| Leucocytes > 10 x10⁹/L        | 0.397  | 0.533 (0.124-2.284)  |         |            |
| Hemoglobin < 120 g/L          | 0.451  | 0.536 (0.106-2.716)  |         |            |
| Platelet count < 100 x10⁹/L   | 0.891  | 1.161 (0.137-9.843)  |         |            |
| TBIL > 17 µmol/L              | 0.252  | 2.344 (0.546-10.058) |         |            |
| PT > 17 s                     | 0.150  | 3.722 (0.700-19.800) |         |            |
| BUN > 7.2 mmol/L              | 0.351  | 2.19 (0.421-11.394)  |         |            |
| Cr > 97 µmol/L                | 0.568  | 1.876 (0.216-16.27)  |         |            |
| Abscess number                | 0.373  | 0.382 (0.046-3.175)  |         |            |
| Diameter of abscess           | 0.960  | 1.029 (0.337-3.141)  |         |            |
| Abscess site                  | 0.093  | 1.822 (0.905-3.667)  | 0.114  | 2.156 (0.832-5.586) |
| Gas forming                   | 0.159  | 5.024 (0.531-47.518) |         |            |
| *Klebsiella pneumonia* infection | 0.297 | 0.315 (0.036-2.758)  |         |            |
| *Escherichia coli* infection  | 0.083  | 2.194 (0.904-5.325)  | 0.101  | 0.226 (0.038-1.339) |
| Treatments                    | 0.940  | 1.046 (0.327-3.344)  |         |            |

TBIL: total bilirubin; PT, prothrombin time; BUN: blood urea nitrogen; Cr: creatinine.

**Table 5.** The clinical characteristics of pyogenic liver abscess with DM between poor-control of glycaemia group and good-control of glycaemia group.
| Variables                              | good-control of Glycaemia (n=23) | poor-control of Glycaemia (n=38) | p value |
|----------------------------------------|----------------------------------|----------------------------------|---------|
| Age (years)                            | 57 (22-84)                       | 58 (23-80)                       | 0.951   |
| Gender (male)                          | 15 (65.22%)                      | 24 (63.16%)                      | 0.871   |
| Diabetes duration (years)              | 5.4 (0.4-27)                     | 5.5 (0.2-30)                     | 0.952   |
| Underlying condition                   |                                  |                                  |         |
| Smoking                                | 8 (34.78%)                       | 8 (21.05%)                       | 0.237   |
| Drinking                               | 5 (21.74%)                       | 5 (13.16%)                       | 0.603   |
| Hypertension                           | 6 (27.27%)                       | 6 (15.79%)                       | 0.461   |
| Laboratory tests                       |                                  |                                  |         |
| WBC > 10 × 10^9/L                      | 7 (30.43%)                       | 16 (42.11%)                      | 0.362   |
| WBC < 3.5 × 10^9/L                     | 2 (8.70%)                        | 1 (2.63%)                        | 0.652   |
| ALT > 40 U/L                           | 12 (52.17%)                      | 13 (34.21%)                      | 0.167   |
| AST > 40 U/L                           | 7 (30.43%)                       | 8 (21.05%)                       | 0.410   |
| ALB < 35 g/L                           | 16 (69.57%)                      | 29 (76.32%)                      | 0.561   |
| TBIL > 17 μmol/L                       | 14 (60.87%)                      | 17 (44.74%)                      | 0.222   |
| PT > 17 s                              | 4 (17.39%)                       | 2 (5.26%)                        | 0.272   |
| APTT > 45 s                            | 3 (13.04%)                       | 4 (10.53%)                       | 0.600   |
| BUN > 7.2 mmol/L                       | 2 (8.70%)                        | 5 (13.51%)                       | 0.697   |
| Cr > 97 μmol/L                         | 2 (8.70%)                        | 5 (13.51%)                       | 0.697   |
| Abscess number                         |                                  |                                  |         |
| Solitary abscess                       | 18 (78.26%)                      | 29 (76.32%)                      | 0.861   |
| Multiple abscess                       | 5 (21.74%)                       | 9 (23.68%)                       |         |
| Maximal diameter of abscess           |                                  |                                  |         |
| ≤ 5 cm                                 | 11 (47.83%)                      | 13 (34.21%)                      | 0.178   |
| 5~10 cm                                | 11 (47.83%)                      | 23 (60.53%)                      |         |
| > 10 cm                                | 1 (4.35%)                        | 2 (5.26%)                        |         |
| Abscess site                           |                                  |                                  |         |
| Left lobe                              | 4 (17.39%)                       | 2 (5.36%)                        | 0.220   |
| Right lobe                             | 13 (56.52%)                      | 30 (78.95%)                      |         |
| Both left and right                    | 5 (21.74%)                       | 4 (10.53%)                       |         |
| Other sites                            | 1 (4.35%)                        | 2 (5.26%)                        |         |
| Klebsiella pneumonia infection         | 4 (17.39%)                       | 11 (28.95%)                      | 0.310   |
| Escherichia coli infection             | 2 (8.70%)                        | 3 (7.89%)                        | 1.000   |
| Treatments                             |                                  |                                  |         |
| Percutaneous drainage                  | 6 (26.09%)                       | 23 (60.53%)                      | 0.027   |
| Surgical drainage                      | 3 (13.04%)                       | 4 (10.53%)                       |         |
| Conservative treatment                 | 14 (60.87%)                      | 11 (28.95%)                      |         |
| Antibiotic use                         |                                  |                                  |         |
| Combined                                | 10 (43.48%)                      | 27 (71.05%)                      | 0.033   |
| Single                                 | 13 (56.52%)                      | 11 (28.95%)                      |         |
| Outcomes                               |                                  |                                  |         |
| Cured                                  | 16 (69.57%)                      | 29 (76.34%)                      | 0.565   |
| Improved                               | 7 (30.43%)                       | 9 (23.68%)                       |         |
| Death                                  | 0 (0%)                           | 0 (0%)                           |         |
| Hospital stay (days)                   | 15 (3-40)                        | 15 (3-28)                        | 0.986   |
| Total Hospitalization expenses (× 10000 yuan) | 2.21 (0.17-5.46) | 4.23 (0.43-19.03) | 0.056   |
| Reoccurrence in three months           | 1 (4.35%)                        | 5 (13.16%)                       | 0.395   |
| Survival (yes/no) in six months        | 17 (73.91%)                      | 33 (86.84%)                      | 0.353   |

WBC: white blood cell; ALT: alanine transaminase; AST: aspartate transaminase; ALB: albumin; TBIL: total bilirubin; PT, prothrombin time; APTT, activated partial thromboplastin time; BUN: blood urea nitrogen; Cr: creatinine.

Figures
Effect of diabetes mellitus on six-month survival in PLA patients after discharge. Differences in short-term survival rates between PLA patients who combined with diabetes (DM group) and those who did not combined with diabetes (Non-DM group). The survival rate was assessed by the Kaplan-Meier analysis and compared by the Log-Rank test.
Effect of controlled blood glycaemia level on six-month survival in PLA patients with diabetes after discharge. Differences in short-term survival rates between PLA patients with diabetes who performed with good-control of glycaemia (Good-control group) and those who did not (Poor-control group). The survival rate was assessed by the Kaplan-Meier analysis and compared by the Log-Rank test.